Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Sponsored by Grail | GRAIL, LLC | GRAIL LLC | GRAIL, Inc. | GRAIL, Inc | GRAIL Inc | GRAIL Inc.
Related tests:


GRAIL Advances the Galleri Registrational Clinical Trial Program (PRNewswire)
"GRAIL, Inc...today provided an update on the PATHFINDER 2 and NHS-Galleri registrational clinical trials evaluating the Galleri multi-cancer early detection (MCED) test. GRAIL has completed the PATHFINDER 2 study's planned enrollment of more than 35,000 participants who are eligible for guideline-recommended cancer screening at more than 30 healthcare institutions in North America. In addition, GRAIL has completed the third and final round of study visits for the NHS-Galleri trial, which enrolled more than 140,000 participants....'We look forward to seeing results from the first 25,000 individuals enrolled in the PATHFINDER 2 study in the second half of 2025 and final results from the NHS-Galleri trial in 2026.'"
Clinical data • Enrollment status
Galleri Test
Illumina completes the divestiture of GRAIL (Illumina Press Release)
"Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company."